APA (7th ed.) Citation

Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., . . . Yoshino, T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: Biomarker analyses of DESTINY-CRC01. Nature Portfolio.

Chicago Style (17th ed.) Citation

Siena, Salvatore, et al. HER2-related Biomarkers Predict Clinical Outcomes with Trastuzumab Deruxtecan Treatment in Patients with HER2-expressing Metastatic Colorectal Cancer: Biomarker Analyses of DESTINY-CRC01. Nature Portfolio.

MLA (9th ed.) Citation

Siena, Salvatore, et al. HER2-related Biomarkers Predict Clinical Outcomes with Trastuzumab Deruxtecan Treatment in Patients with HER2-expressing Metastatic Colorectal Cancer: Biomarker Analyses of DESTINY-CRC01. Nature Portfolio.